Molecular status of RBICCI in various disea,and trial for the clinical application

为了明确RB1CC1 （RB1-inducible coil -coil - 1）在各种人类疾病中的分子地位，我们启动了这个项目，并打算将分子途径应用于临床医学。因此，我们发现RB1CC1不足通过不平衡的TSC1丰度导致mTOR信号抑制，诱导神经元萎缩，进而参与阿尔茨海默病的发病机制。最近，我们的研究还表明，RB1CC1是连接RB1和p53通路的新型介质，RB1CC1和p53状态的联合评估将为乳腺癌患者提供常规、准确的预后检测。

To clarify the molecular status of RB1CC1 (RB1-inducible coiled-coil 1) in various human diseases, we started this project, and have intended to apply the molecular pathways into clinical medicine.In a consequence, we identified that RB1CC1 insufficiency resulted in mTOR signaling repression through unbalanced TSC1 abundance, induced neuronal atrophy, and then were involved in the pathogenesis of Alzheimer's disease.More recently, our study also has demonstrated that RB1CC1 is a novel mediator connecting the RB1 and p53 pathways, and that the combined evaluation of RB1CC1 and p53 status will provide a routine, accurate prognostic test for patients with breast cancer.